CD8A and neoplasm: Programmed death‐ligand 1 (PD‐L1) on the surface of tumour‐EVs can suppress CD8+ T‐cell function and allow tumour expansion (Chen et al., 2018), while surface complement proteins skew B cells and monocytes towards an anti‐inflammatory phenotype (Koppler et al., 2006).